Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Aptevo Therapeutics Inc. | apvo-10k_20161231.htm |
| EX-32.1 - EX-32.1 - Aptevo Therapeutics Inc. | apvo-ex321_439.htm |
| EX-31.2 - EX-31.2 - Aptevo Therapeutics Inc. | apvo-ex312_440.htm |
| EX-31.1 - EX-31.1 - Aptevo Therapeutics Inc. | apvo-ex311_441.htm |
| EX-23.1 - EX-23.1 - Aptevo Therapeutics Inc. | apvo-ex231_442.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Aptevo Therapeutics Inc. (the “Company”) for the period ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Jeffrey G. Lamothe, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(1) The Report to which this Certification is attached as Exhibit 32.2 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: March 31, 2017 |
|
By: |
/s/ Jeffrey G. Lamothe |
|
|
|
|
Jeffrey G. Lamothe |
|
|
|
|
Senior Vice President, Chief Financial Officer, and Treasurer |
“This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of _Aptevo Therapeutics Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.”